Kymera COO exercises options, sells 6,551 shares
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported option exercises and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported option exercises and related share sales. On April 14–15, 2026, he exercised stock options to acquire a total of 6,551 shares of common stock at exercise prices of $30.17 and $43.50 per share.
On the same dates, he sold 6,551 common shares in open-market transactions at prices around $90.00 to $90.10 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 61,202 Kymera Therapeutics shares.
Insider Trade Summary 10b5-1
Exercise and Sale: 6,551 shares ($364K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Chadwick Jeremy G
Role
Chief Operating Officer
Sold
6,551 shs ($590K)
Approx. gross sale proceeds
$590K
Approx. exercise cost
$225K
Approx. pre-tax spread
$364K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,300 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,300 | $43.50 | $57K |
| Sale | Common Stock | 1,300 | $90.00 | $117K |
| Exercise | Stock Option (Right to Buy) | 4,466 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 785 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,466 | $30.17 | $135K |
| Exercise | Common Stock | 785 | $43.50 | $34K |
| Sale | Common Stock | 5,251 | $90.0016 | $473K |
Holdings After Transaction:
Stock Option (Right to Buy) — 103,997 contracts (Direct);
Common Stock — 61,202 shares (Direct)
Footnotes (4)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
- F4. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
Key Figures
Shares sold: 6,551 shares
Option exercise prices: $30.17 and $43.50 per share
Sale price range: $90.00–$90.10 per share
+2 more
5 metrics
Shares sold
6,551 shares
Total common shares sold in open-market transactions
Option exercise prices
$30.17 and $43.50 per share
Strike prices for exercised stock options
Sale price range
$90.00–$90.10 per share
Weighted-average range for common stock sales
Shares after transactions
61,202 shares
Direct common stock ownership after April 14–15, 2026
Options exercised
6,551 options
Total stock options exercised across reported transactions
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vest in thirty-six (36) equal monthly installments financial
"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kymera Therapeutics (KYMR) COO Jeremy Chadwick report in this Form 4?
He exercised stock options for 6,551 Kymera Therapeutics shares and sold 6,551 shares in open-market transactions around $90 per share, all under a pre-arranged Rule 10b5-1 trading plan, and ended with 61,202 shares held directly.
What stock options did the Kymera Therapeutics (KYMR) COO exercise?
He exercised stock options covering 6,551 shares of Kymera common stock. The options had exercise prices of $30.17 and $43.50 per share and were granted under awards that vest in 36 equal monthly installments, subject to continued employment.
What are the vesting terms of the Kymera Therapeutics (KYMR) stock options exercised?
The footnotes explain that the options’ underlying shares vest in thirty-six equal monthly installments following March 1, 2024, and March 3, 2025. Vesting continues only if the reporting person remains employed through each applicable monthly vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates